INDRAPRASTHA MEDICAL 2018-19 Annual Report Analysis

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDRAPRASTHA MEDICAL 2018-19 Annual Report Analysis
Fri, 18 Oct

INDRAPRASTHA MEDICAL has announced its results for the year ended March 2019. Let us have a look at the detailed performance review of the company during FY18-19.

INDRAPRASTHA MEDICAL Income Statement Analysis

  • Operating income during the year rose 4.7% on a year-on-year (YoY) basis.
  • The company's operating profit increased by 11.0% YoY during the fiscal. Operating profit margins witnessed a growth and stood at 10.2% in FY19 as against 9.7% in FY18.
  • Depreciation charges decreased by 3.0% and finance costs decreased by 22.8% YoY, respectively.
  • Other income declined by 41.0% YoY.
  • Net profit for the year grew by 34.6% YoY.
  • Net profit margins during the year grew from 2.8% in FY18 to 3.6% in FY19.

INDRAPRASTHA MEDICAL Income Statement 2018-19

No. of Mths Year Ending12 Mar-18*12 Mar-19*% Change
Net SalesRs m7,5277,8824.7%
Other incomeRs m85-41.0%
Total RevenuesRs m7,5357,8864.7%
Gross profitRs m72880811.0%
DepreciationRs m307298-3.0%
InterestRs m8969-22.8%
Profit before taxRs m34044631.2%
TaxRs m12916225.6%
Profit after taxRs m21128434.6%
Gross profit margin%9.710.2
Effective tax rate%37.936.3
Net profit margin%2.83.6
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



DISCOVER: How to Potentially Multiply Your Returns by Upto 5x...

INDRAPRASTHA MEDICAL Balance Sheet Analysis

  • The company's current liabilities during FY19 down at Rs 1 billion as compared to Rs 1 billion in FY18, thereby witnessing an decrease of -10.4%.
  • Long-term debt down at Rs 150 million as compared to Rs 210 million during FY18, a fall of 28.6%.
  • Current assets rose 2% and stood at Rs 1 billion, while fixed assets fell 4% and stood at Rs 3 billion in FY19.
  • Overall, the total assets and liabilities for FY19 stood at Rs 4 billion as against Rs 4 billion during FY18, thereby witnessing a fall of 2%.

INDRAPRASTHA MEDICAL Balance Sheet as on March 2019

No. of Mths Year Ending12 Mar-18*12 Mar-19*% Change
NetworthRs m2,3232,4405.0
 
Current LiabilitiesRs m1,3841,241-10.4
Long-term DebtRs m210150-28.6
Total LiabilitiesRs m4,3234,224-2.3
 
Current assetsRs m1,3291,3562.0
Fixed AssetsRs m 2,9402,814-4.3
Total AssetsRs m4,3234,224-2.3
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



INDRAPRASTHA MEDICAL Cash Flow Statement Analysis

  • INDRAPRASTHA MEDICAL's cash flow from operating activities (CFO) during FY19 stood at Rs 752 million, an improvement of 57.6% on a YoY basis.
  • Cash flow from investing activities (CFI) during FY19 stood at Rs -167 million on a YoY basis.
  • Cash flow from financial activities (CFF) during FY19 stood at Rs -442 million on a YoY basis.
  • Overall, net cash flows for the company during FY19 stood at Rs 143 million from the Rs 6 million net cash flows seen during FY18.

INDRAPRASTHA MEDICAL Cash Flow Statement 2018-19

ParticularsNo. of months1212% Change
Year EndingMar-18Mar-19
Cash Flow from Operating ActivitiesRs m47775257.6%
Cash Flow from Investing ActivitiesRs m-299-167-
Cash Flow from Financing ActivitiesRs m-172-442-
Net Cash FlowRs m61432,365.5%
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



Current Valuations for INDRAPRASTHA MEDICAL

  • The trailing twelve-month earnings per share (EPS) of the company stands at Rs 3.1, an improvement from the EPS of Rs 2.3 recorded last year.
  • The price to earnings (P/E) ratio, at the current price of Rs 36.1, stands at 10.9 times its trailing twelve months earnings.
  • The price to book value (P/BV) ratio at current price levels stands at 1.7 times, while the price to sales ratio stands at 0.5 times.
  • The company's price to cash flow (P/CF) ratio stood at 5.7 times its end-of-year operating cash flow earnings.

Per Share Data/Valuations

No. of Mths Year Ending12 Mar-18*12 Mar-19*
Sales per share (Unadj.)Rs82.186.0
TTM Earnings per shareRs2.33.1
Diluted earnings per shareRs2.33.1
Price to Cash Flow x6.45.7
TTM P/E ratiox10.910.9
Price / Book Value ratiox2.31.7
Market CapRs m3,3093,309
Dividends per share (Unadj.)Rs1.51.6
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



Ratio Analysis for INDRAPRASTHA MEDICAL

  • Solvency Ratios
  • Current Ratio: The company's current ratio improved and stood at 1.1x during FY19, from 1.0x during FY18. The current ratio measures the company's ability to pay short-term and long-term obligations.

    Interest Coverage Ratio: The company's interest coverage ratio improved and stood at 7.5x during FY19, from 4.8x during FY18. The interest coverage ratio of a company states how easily a company can pay its interest expense on outstanding debt. A higher ratio is preferable.

  • Profitability Ratios
  • Return on Equity (ROE): The ROE for the company improved and stood at 11.6% during FY19, from 9.1% during FY19. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.

    Return on Capital Employed (ROCE): The ROCE for the company improved and stood at 19.9% during FY19, from 16.9% during FY18. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.

    Return on Assets (ROA): The ROA of the company improved and stood at 8.4% during FY19, from 6.9% during FY18. The ROA measures how efficiently the company uses its assets to generate earnings.

Key Ratio Analysis

No. of Mths Year Ending12 Mar-18*12 Mar-19*
Current ratiox1.01.1
Debtors’ DaysDays4135
Interest coveragex4.87.5
Debt to equity ratiox0.10.1
Return on assets%6.98.4
Return on equity%9.111.6
Return on capital employed%16.919.9
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



To see how INDRAPRASTHA MEDICAL has performed over the last 5 years, please visit here.

INDRAPRASTHA MEDICAL Share Price Performance

Over the last one year, INDRAPRASTHA MEDICAL share price has moved down from Rs 40.4 to Rs 36.1, registering a loss of Rs 4.3 or around 10.6%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 12,628.2 (up 1.0%). Over the last one year it has moved down from 14,640.1 to 12,628.2, a loss of 2,012 points (down 13.7%).

Overall, the S&P BSE SENSEX is up 12.8% over the year.

(To know more, check out historical annual results for INDRAPRASTHA MEDICAL and quarterly results for INDRAPRASTHA MEDICAL)

Equitymaster requests your view! Post a comment on "INDRAPRASTHA MEDICAL 2018-19 Annual Report Analysis". Click here!

  

Related Views on News

INDRAPRASTHA MEDICAL Announces Quarterly Results (4QFY20); Net Profit Down 9.0% (Quarterly Result Update)

May 26, 2020 | Updated on May 26, 2020

For the quarter ended March 2020, INDRAPRASTHA MEDICAL has posted a net profit of Rs 65 m (down 9.0% YoY). Sales on the other hand came in at Rs 2 bn (up 0.0% YoY). Read on for a complete analysis of INDRAPRASTHA MEDICAL's quarterly results.

INDRAPRASTHA MEDICAL Announces Quarterly Results (2QFY20); Net Profit Up 133.6% (Quarterly Result Update)

Nov 8, 2019 | Updated on Nov 8, 2019

For the quarter ended September 2019, INDRAPRASTHA MEDICAL has posted a net profit of Rs 179 m (up 133.6% YoY). Sales on the other hand came in at Rs 2 bn (up 8.0% YoY). Read on for a complete analysis of INDRAPRASTHA MEDICAL's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

How Much Money For Day Trading?(Fast Profits Daily)

Feb 22, 2021

In this video, I'll show you how to allocate your capital as a day trader.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

TRACK INDRAPRASTHA MEDICAL

  • Track your investment in INDRAPRASTHA MEDICAL with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDRAPRASTHA MEDICAL

INDRAPRASTHA MEDICAL 5-YR ANALYSIS

COMPARE INDRAPRASTHA MEDICAL WITH

MARKET STATS